Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive stage small cell lung cancer (ED-SCLC) (final report).

Abstract

7206 Background: Amrubicin (AMR), a totally synthetic 9-amino-anthracycline, demonstrated excellent single agent activity for ED-SCLC (Yana et al., Proc. ASCO, 1998, abstr.#1734). The aim of this trial was to determine the maximum-tolerated doses (MTDs) of combination therapy of AMR with cisplatin (CDDP), in order to assess the efficacy for ED-SCLC… (More)

Topics

Cite this paper

@article{Ohe2004PhaseIS, title={Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive stage small cell lung cancer (ED-SCLC) (final report).}, author={Yasuo Ohe and Seiji Negoro and K. Matsui and K. Nakagawa and T. Sugiura and Y. Takada and Yutaka Nishiwaki and Nagahiro George Saijo and Masahiro Fukuoka and Yutaka Ariyoshi}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2004}, volume={22 14_suppl}, pages={7206} }